Munich, Germany \u2014 Life science inves\u00adtors Andera Part\u00adners, Evotec and Fund+ are advi\u00adsing on a EUR 60 million (USD 63 million) Series B finan\u00adcing for Tubu\u00adlis GmbH. All exis\u00adting inves\u00adtors also parti\u00adci\u00adpa\u00adted in the round, inclu\u00adding Bayern Kapi\u00adtal (with Wachs\u00adtums\u00adfonds Bayern 2), BioMed\u00adPart\u00adners, copa\u00adrion, High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF), OCCIDENT and Seven\u00adture Partners.<\/p>\n
The new capi\u00adtal will be used to advance Tubu\u00adlis\u2019 proprie\u00adtary pipe\u00adline of uniquely assem\u00adbled anti\u00adbody-drug conju\u00adga\u00adtes (ADCs) toward clini\u00adcal evalua\u00adtion and launch programs for a range of solid tumor indi\u00adca\u00adti\u00adons. The new capi\u00adtal is expec\u00adted to enable the company to realize the true thera\u00adpeu\u00adtic poten\u00adtial of ADCs through further inno\u00adva\u00adtion in new drug clas\u00adses and the iden\u00adti\u00adfi\u00adca\u00adtion of novel cancer targets.<\/p>\n
Tubu\u00adlis uses proprie\u00adtary tech\u00adno\u00adlo\u00adgies to deve\u00adlop novel drugs whose mecha\u00adnisms of action go deep at the root cause of the dise\u00adase in ques\u00adtion. The goal is to expand the thera\u00adpeu\u00adtic poten\u00adtial of anti\u00adbody-drug conju\u00adga\u00adtes (ADCs) to enable more targe\u00adted and effec\u00adtive therapy of cancer as well as other diseases.<\/p>\n
Andera Part\u00adners<\/strong> was foun\u00added over 20 years ago and is a key player in private equity invest\u00adments inside and outside France. Andera teams manage more than \u20ac3.2 billion of invest\u00adment capi\u00adtal in life scien\u00adces (Andera Life Scien\u00adces), growth and buyout capi\u00adtal (Andera MidCap, Andera Expan\u00adsion, Andera Crois\u00adsance, Andera Co-Invest), non-spon\u00adsor tran\u00adsac\u00adtions (Andera Acto), and envi\u00adron\u00admen\u00adtal trans\u00adfor\u00adma\u00adtion (Andera Infra). The Andera Life Scien\u00adces team has raised over \u20ac1.1 billion through the BioDis\u00adco\u00advery family of funds and is curr\u00adently inves\u00adt\u00ading from the BioDis\u00adco\u00advery 6 fund.<\/p>\n Evotec<\/strong> is a life science company with a unique busi\u00adness model dedi\u00adca\u00adted to disco\u00adve\u00adring, deve\u00adlo\u00adping and deli\u00adve\u00adring highly effec\u00adtive thera\u00adpeu\u00adtics to pati\u00adents. The company\u2019s multi\u00admo\u00addal plat\u00adform includes a unique combi\u00adna\u00adtion of inno\u00adva\u00adtive tech\u00adno\u00adlo\u00adgies, data and science for the disco\u00advery, deve\u00adlo\u00adp\u00adment and produc\u00adtion of world-class phar\u00admaceu\u00adti\u00adcal products.<\/p>\n Fund+<\/strong> is a Belgian venture capi\u00adtal firm that invests in inno\u00adva\u00adtive Euro\u00adpean life scien\u00adces compa\u00adnies deve\u00adlo\u00adping drugs, medi\u00adcal devices and diagno\u00adstics, with a focus on pati\u00adent-centric approa\u00adches and large unmet medi\u00adcal needs. With over \u20ac200 million in assets under manage\u00adment, Fund+ has a solid track record since 2015, inves\u00adt\u00ading in 17 port\u00adfo\u00adlio compa\u00adnies with two major exits.<\/p>\n Andera Part\u00adners, Evotec and Fund+ were advi\u00adsed on this tran\u00adsac\u00adtion by Baker McKen\u00adzie\u2019s Corporate\/M&A and Life Science teams. They regu\u00adlarly advise phar\u00admaceu\u00adti\u00adcal compa\u00adnies, finan\u00adcial inves\u00adtors, stra\u00adte\u00adgic inves\u00adtors and biotech\u00adno\u00adlogy compa\u00adnies on natio\u00adnal and inter\u00adna\u00adtio\u00adnal health\u00adcare tran\u00adsac\u00adtions. Most recently, Baker McKen\u00adzie advi\u00adsed, among others, Alle\u00adcra Thera\u00adpeu\u00adtics on an exclu\u00adsive license and supply agree\u00adment with ADVANZ PHARMA, MODAG on a stra\u00adte\u00adgic colla\u00adbo\u00adra\u00adtion with Teva, Chord Thera\u00adpeu\u00adtics on its sale to Merck KGaA, LSP as lead inves\u00adtor in a EUR 20 million Series A equity finan\u00adcing of Inno\u00adva\u00adtive Mole\u00adcu\u00adles, Numab Thera\u00adpeu\u00adtics in a CHF 100 million cross-over finan\u00adcing, Cata\u00adlYm in a EUR 50 million Series B finan\u00adcing led by Vesa\u00adlius Capi\u00adtal, Casdin Capi\u00adtal as lead inves\u00adtor in DNA Scrip\u00adt\u2019s USD 50 million exten\u00added Series B equity finan\u00adcing round, and Chr. Hansen Holding in its acqui\u00adsi\u00adtion of Jenne\u00adwein Biotechnology.<\/p>\n Legal Coun\u00adsel Andera Part\u00adners, Evotec and Fund+: Baker McKenzie<\/strong> Munich, Germany \u2014 Life science inves\u00adtors Andera Part\u00adners, Evotec and Fund+ are advi\u00adsing on a EUR 60 million (USD 63 million) Series B finan\u00adcing for Tubu\u00adlis GmbH. All exis\u00adting inves\u00adtors also parti\u00adci\u00adpa\u00adted in the round, inclu\u00adding Bayern Kapi\u00adtal (with Wachs\u00adtums\u00adfonds Bayern 2), BioMed\u00adPart\u00adners, copa\u00adrion, High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF), OCCIDENT and Seven\u00adture Part\u00adners. The new capi\u00adtal will [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":39819,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1367,1369],"tags":[],"class_list":["post-39913","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-investors"],"yoast_head":"\n
\nLead Part\u00adner Julia Braun, LL.M. (Part\u00adner, Munich); Corporate\/M&A: Bert\u00adhold Hummel (Part\u00adner, Munich), Dr. Julia Rossie (Asso\u00adciate, Munich)
\nTran\u00adsac\u00adtional IP: Julia Schie\u00adber (Senior Asso\u00adciate, Zurich)
\nForeign Trade Law: Alex\u00adan\u00adder Ehrle, Kimber\u00adley Fischer (both Asso\u00adcia\u00adtes, Berlin)
\nEmploy\u00adment Law: Dr. Matthias K\u00f6hler (Part\u00adner, Berlin), Kers\u00adtin Schmie\u00addel (Asso\u00adciate, Berlin)<\/p>\n","protected":false},"excerpt":{"rendered":"